Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Go back to Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment| Otter Lake Resources, Inc. New (NASDAQ: OTLK) | Delayed: 0.69 +0.01 (1.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.68 | 52 Week High | $0.03 | |||
| Open | $0.70 | 52 Week Low | $0.01 | |||
| Day High | $0.71 | P/E | N/A | |||
| Day Low | $0.69 | EPS | $0.00 | |||
| Volume | 697,095 | |||||
